Elsevier

Progress in Cardiovascular Diseases

Volume 62, Issue 6, November–December 2019, Pages 447-451
Progress in Cardiovascular Diseases

Tricuspid regurgitation is a public health crisis

https://doi.org/10.1016/j.pcad.2019.10.009Get rights and content

Abstract

Tricuspid regurgitation (TR) has long been a forgotten valve disease of benign reputation. However, TR deserves higher attention and represents a growing public health crisis. Indeed, recent epidemiological data suggest that 1.6 million US residents are affected by moderate or severe TR. Furthermore, large recent cohorts demonstrate that higher degrees of TR are associated with considerable excess mortality, independent of all background clinical and hemodynamic contexts. Finally, analysis of recent cohorts also shows that >90% of patients with moderate or severe TR are never offered surgical treatment and remain untreated. Therefore, TR is frequent, severely impacts outcomes, and is rarely treated, justifying the development of new strategies and methods for its treatment.

Introduction

Tricuspid regurgitation (TR) is a valvular condition which is frequent and has long been perceived as being well-known and well-understood.1 Therefore, the claim that TR represents a public health crisis is not simple to comprehend. Unfortunately, the concept of public health crisis is poorly defined and may be misunderstood for a public health emergency. In our opinion, the first element is the frequency of the condition; indeed, a rare condition may be very serious and warranting treatment but cannot amount to a public health crisis. The second element besides the frequency of the condition is its impact on outcome. A frequent condition that is benign cannot become a public health crisis. The third element to consider is the limited treatment received by the carriers of the condition, whether the treatment is often ineffective or whether an effective treatment is not administered.

TR is defined by the regurgitation of blood from the right ventricle (RV) to the right atrium, which is normally prevented by the coaptation of the tricuspid leaflets during systole.1,2 Because presence of at least trivial TR is discovered in the vast majority of subjects, even with completely normal hearts, it is indispensable to consider trivial TR as physiologic in most subjects and thus inconsequential.1,2 Hence, the grading of TR by Doppler-echocardiography is crucial.3 While the clinical significance of mild TR is most often considered benign, the TR that deserves the most attention is severe TR, and most recent data suggests that even moderate TR is also consequential and warrants our attention.4 Therefore, the question to be examined is whether moderate or severe TR among our national community represents a public health crisis by fulfilling all three criteria of frequency, poor outcome and insufficient/ineffective treatment. Unfortunately, in view of its previous reputation of a benign condition,5 the background knowledge regarding TR has remained quite scarce and because TR is also heterogeneous6 the literature may be quite confusing and uncertain.

Section snippets

Epidemiology of TR: is TR a frequent condition?

The epidemiology of TR is poorly known. Similar to other valve diseases the clinical examination is generally unrevealing7,8 and many cases of confirmed TR are undetected clinically. This lack of sensitivity of clinical examination for TR makes Doppler-echocardiography the main tool for detecting TR in the population.1 Color flow imaging is highly sensitive for TR, which has been shown to be quite frequent in the normal population. The American Society of Echocardiography has provided

Outcome of TR: is TR a serious condition?

This question is the most difficult to answer as historical data provided blanket answers that were contradictory. Indeed, on one hand TR was recommended as benign enough to require only conservative management5 and it was even estimated that complete surgical removal of the tricuspid valve was associated with excellent tolerance and outcome.15 On the other hand TR diagnosed by echocardiography, irrespective of its cause, was found overall to severely impact outcome.16 These contradictory

Treatment of TR: is there an unmet need for treatment?

The only currently approved treatment for TR is cardiac surgery with tricuspid valve repair or replacement.31 The only class I indication for TR surgery is for severe TR in the context of mitral surgery. To consider whether the need for treatment is met or not, one must consider effectiveness of surgical treatment and the consistency and frequency of treatment application.

TR public health crisis: the way forward

With TR now proven to bear the hallmarks of a public health crisis as a condition that is frequent in the population, affecting millions of mostly older patients, complicated by severe HF and excess mortality and treated only in a minimal fraction of those affected, it is abundantly clear that a plan of action is necessary. The way forward involves:

  • 1.

    Paying more attention to diagnosing moderate and severe TR, which ideally encompasses increased use of quantitative Doppler-echocardiographic

Statement of conflict of interest

None of the authors have any conflicts of interests with regard to this publication.

References (40)

  • D Messika-Zeitoun et al.

    Medical and surgical outcome of tricuspid regurgitation caused by flail leaflets

    J Thorac Cardiovasc Surg

    (2004)
  • G Lin et al.

    Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads

    J Am Coll Cardiol

    (2005)
  • CM Van De Heyning et al.

    Prospective study of tricuspid regurgitation associated with permanent leads after cardiac rhythm device implantation

    Can J Cardiol

    (2019)
  • SS Kazum et al.

    Prevalence, echocardiographic correlations, and clinical outcome of tricuspid regurgitation in patients with significant left ventricular dysfunction

    Am J Med

    (2019)
  • A Sagie et al.

    Significant tricuspid regurgitation is a marker for adverse outcome in patients undergoing percutaneous balloon mitral valvuloplasty

    J Am Coll Cardiol

    (1994)
  • Y Topilsky et al.

    Clinical outcome of isolated tricuspid regurgitation

    J Am Coll Cardiol Img

    (2014)
  • EA Fender et al.

    Prognostic importance and predictors of survival in isolated tricuspid regurgitation: a growing problem

    Mayo Clin Proc

    (2019)
  • A Anselmi et al.

    Appraisal of long-term outcomes of tricuspid valve replacement in the current perspective

    Ann Thorac Surg

    (2016)
  • A Kilic et al.

    Trends and outcomes of tricuspid valve surgery in North America: an analysis of more than 50,000 patients from the Society of Thoracic Surgeons database

    Ann Thorac Surg

    (2013)
  • J Dreyfus et al.

    Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a French nationwide database)

    Am J Cardiol

    (2018)
  • Cited by (55)

    View all citing articles on Scopus

    Statement of conflict of interest: see page 451.

    View full text